Research from industry analyst GlobalData highlights the significance of the pediatric treatment opportunity for Novartis’ (NOVN: VX) Entresto (sacubitril/valsartan).
The European Medicines Agency (EMA) granted approval for the treatment of adults with symptomatic chronic heart failure in 2015.
The company now looks set to expand the label in Europe, with the EMA’s Committee for Medicinal Products for Human Use (CHMP) having recommended approval for children as young as one.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze